Kymera Therapeutics, Inc.
KYMR
$117.39
$2.972.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -61.21M | -69.23M | -86.98M | -82.18M | -76.61M |
| Total Depreciation and Amortization | 2.03M | 2.02M | 2.03M | 2.15M | 2.08M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.61M | 13.28M | 12.41M | 17.47M | 13.30M |
| Change in Net Operating Assets | -11.50M | -34.91M | 5.79M | 35.45M | 1.35M |
| Cash from Operations | -54.07M | -88.84M | -66.75M | -27.11M | -59.88M |
| Capital Expenditure | -473.00K | -434.00K | -106.00K | -181.00K | -695.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.52M | -142.41M | -394.29M | -235.12M | 60.72M |
| Cash from Investing | 20.05M | -142.84M | -394.40M | -235.30M | 60.02M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -436.00K | -425.00K | -416.00K | -419.00K | -382.00K |
| Issuance of Common Stock | 14.86M | 19.19M | 757.54M | 39.93M | 246.11M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -51.90M | -- | -- |
| Cash from Financing | 14.42M | 18.77M | 705.22M | 39.51M | 245.73M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -19.60M | -212.91M | 244.07M | -222.90M | 245.86M |